190 related articles for article (PubMed ID: 34751039)
21. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
Dimitriou F; Zaremba A; Allayous C; Kähler KC; Gerard CL; Festino L; Schäfer S; Toussaint F; Heinzerling L; Hassel JC; Ascierto PA; Michielin O; Hauschild A; Lebbe C; Livingstone E; Ramelyte E; Cheng PF; Dummer R; Mangana J
Eur J Cancer; 2021 May; 149():37-48. PubMed ID: 33823361
[TBL] [Abstract][Full Text] [Related]
22. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
23. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
24. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
25. Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report.
Soellradl I; Kehrer H; Cejka D
Transplant Proc; 2020 Mar; 52(2):657-659. PubMed ID: 32044081
[TBL] [Abstract][Full Text] [Related]
26. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.
Aguirre LE; Guzman ME; Lopes G; Hurley J
Oncologist; 2019 Mar; 24(3):394-401. PubMed ID: 30413665
[TBL] [Abstract][Full Text] [Related]
28. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
29. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
30. Liver graft rejection following immune checkpoint inhibitors treatment: a review.
Hu B; Yang XB; Sang XT
Med Oncol; 2019 Oct; 36(11):94. PubMed ID: 31605245
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitors in Recipients of Renal Allografts.
Venkataraman K; Salehi T; Carroll RP
Semin Nephrol; 2024 Jan; 44(1):151500. PubMed ID: 38548484
[TBL] [Abstract][Full Text] [Related]
32. Clinical Challenges of Immune Checkpoint Inhibitors.
de Miguel M; Calvo E
Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319
[TBL] [Abstract][Full Text] [Related]
33. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
34. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
[TBL] [Abstract][Full Text] [Related]
35. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
Olbryt M; Rajczykowski M; Widłak W
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
[TBL] [Abstract][Full Text] [Related]
36. Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.
Alhamad T; Venkatachalam K; Linette GP; Brennan DC
Am J Transplant; 2016 Apr; 16(4):1332-3. PubMed ID: 26752406
[No Abstract] [Full Text] [Related]
37. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
[TBL] [Abstract][Full Text] [Related]
38. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
39. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for advanced melanoma: current situation in Japan.
Kato J; Uhara H
Jpn J Clin Oncol; 2021 Jan; 51(1):3-9. PubMed ID: 33140101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
